Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment
- PMID: 16355319
- DOI: 10.1086/499404
Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment
Abstract
Antimicrobial resistance in health care-associated pathogens is a growing concern for health care and for public health. A recent shift in the epidemiological profile of methicillin-resistant Staphylococcus aureus has resulted not only in health care-associated infections but now, also, in community-associated infections. Reports have described S. aureus exhibiting decreased susceptibility and, even, resistance to vancomycin. The rate of vancomycin resistance among enterococci may be leveling; however, vancomycin resistance in Enterococcus faecium has already achieved high levels. Multidrug resistance in Pseudomonas aeruginosa is increasing, and carbapenem-resistant Klebsiella strains are emerging. Acinetobacter species cause a minority of health care-associated pneumonias due to gram-negative organisms, but a growing proportion is resistant to carbapenems and third-generation cephalosporins. Recent increases in the frequency and severity of Clostridium difficile-associated illness are associated with the emergence of a hypervirulent C. difficile strain with increased resistance to the fluoroquinolones. The presence of these and other resistant organisms in health care facilities limits the number of effective antimicrobials available for treatment.
Similar articles
-
Antimicrobial resistance in Europe and its potential impact on empirical therapy.Clin Microbiol Infect. 2008 Dec;14 Suppl 6:2-8. doi: 10.1111/j.1469-0691.2008.02126.x. Clin Microbiol Infect. 2008. PMID: 19040461 Review.
-
Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.J Microbiol Immunol Infect. 2006 Apr;39(2):135-43. J Microbiol Immunol Infect. 2006. PMID: 16604246
-
Antimicrobial resistance in gram-positive bacteria.Am J Infect Control. 2006 Jun;34(5 Suppl 1):S11-9; discussion S64-73. doi: 10.1016/j.ajic.2006.05.220. Am J Infect Control. 2006. PMID: 16813977 Review.
-
Advances in antibacterial therapy against emerging bacterial pathogens.Semin Hematol. 2009 Jul;46(3):198-211. doi: 10.1053/j.seminhematol.2009.03.007. Semin Hematol. 2009. PMID: 19549574 Review.
-
The current state of multidrug-resistant gram-negative bacilli in North America.Pharmacotherapy. 2008 Feb;28(2):235-49. doi: 10.1592/phco.28.2.235. Pharmacotherapy. 2008. PMID: 18225969 Review.
Cited by
-
Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils.Pathog Dis. 2017 Aug 31;75(6):ftx075. doi: 10.1093/femspd/ftx075. Pathog Dis. 2017. PMID: 28859309 Free PMC article.
-
Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.Clin Pharmacokinet. 2009;48(4):273-80. doi: 10.2165/00003088-200948040-00005. Clin Pharmacokinet. 2009. PMID: 19492872
-
The evolution of antibiotic resistance in Europe, 1998-2019.PLoS Pathog. 2025 Apr 3;21(4):e1012945. doi: 10.1371/journal.ppat.1012945. eCollection 2025. PLoS Pathog. 2025. PMID: 40179072 Free PMC article.
-
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).World J Emerg Surg. 2016 Jul 15;11:33. doi: 10.1186/s13017-016-0089-y. eCollection 2016. World J Emerg Surg. 2016. PMID: 27429642 Free PMC article. Review.
-
Antibiotic persistence and its impact on the environment.3 Biotech. 2023 Dec;13(12):401. doi: 10.1007/s13205-023-03806-6. Epub 2023 Nov 16. 3 Biotech. 2023. PMID: 37982084 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical